UroGen Pharma (URGN) Peer Comparison
$43.62
$-1.88
(-4.13%)
As on 28-Aug-2026 16:00EDT
Market cap
$2,291 Mln
Revenue (TTM)
$189 Mln
P/E Ratio
--
P/B Ratio
19.3
Div. Yield
0 %
Edit
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,291 | 248 | 254 | 9 | 4 |
Revenue ($ Mln) |
189 | 74 | 2 | 1 | -- |
Net Profit ($ Mln) |
-97.64 | 35.19 | -16.34 | -9.07 | -13.44 |
Net Margin (%) |
-51.73 | 47.55 | -910.14 | -694.19 | -- |
RoE (%) |
-- | 36.76 | -46.08 | -- | -90.40 |
Price to Earnings |
-- | 7.07 | -- | -- | -- |
Price-To-Book |
19.27 | 2.84 | 5.25 | 6.18 | 0.33 |
Cashflow ($ Mln)
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-162.44 | 31.63 | 0.32 | -13.50 | -6.32 |
|
Cash Flow from Investing Activities
|
61.56 | 30.00 | -8.58 | 17.74 | -3.38 |
|
Cash from Financing Activities
|
39.92 | 10.60 | 0.01 | -6.60 | 9.03 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-223.36 | 43.23 | -22.71 | -125.34 | -64.21 |
|
ROE (%)
|
268.63 | 36.76 | -46.08 | 1,106.98 | -90.40 |
|
ROA (%)
|
-34.21 | 24.43 | -21.91 | -24.72 | -46.81 |
|
EBIT Margin (%)
|
-38.55 | 0.00 | 0.00 | -1,029.84 | -- |
|
Net Margin (%)
|
-51.73 | 47.55 | -910.14 | -694.19 | -- |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | 0.00 | -- |
Growth Ratios
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
100.27 | 234.18 | -92.50 | -80.43 | -- |
|
EBIT Growth (%)
|
44.16 | -- | -- | -8.41 | 34.71 |
|
Net Profit Growth (%)
|
37.00 | 281.73 | -379.09 | 36.34 | -54.07 |
|
EPS Growth (%)
|
40.19 | 276.06 | -424.44 | 59.44 | 10.84 |
|
Book Value Growth (%)
|
-34.36 | 74.49 | 28.50 | 45.11 | -59.29 |
Valuation Ratios
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-7.51 | 4.10 | -19.16 | -1.13 | -0.48 |
|
Price / Book Value
|
-10.93 | 1.41 | 5.15 | -116.95 | 0.31 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-8.56 | 0.06 | -12.71 | 0.10 | 1.28 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.43 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-0.02 | 0.01 | 0.01 | -0.20 | 0.00 |
|
Current Ratio
|
3.80 | 5.72 | 10.37 | 3.57 | 7.71 |
|
Quick Ratio
|
3.41 | 5.72 | 10.37 | 3.54 | 7.71 |
|
Interest Coverage
|
-1.84 | -- | -- | -2.21 | -- |
Operating Efficiency Ratios
| UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | Galmed Pharmaceuticals - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
47.03 | 5.55 | 39.72 | 29.38 | -- |
|
Asset Turnover
|
0.66 | 0.51 | 0.02 | 0.04 | 0.00 |
|
Receivable days
|
88.80 | 1.41 | 52.40 | 135.80 | -- |
|
Inventory Days
|
376.94 | -- | -- | 90.51 | -- |
|
Payable days
|
338.46 | 82.73 | 3,350.92 | 83.28 | -- |
|
Cash Conversion Cycle
|
127.29 | -- | -- | 143.02 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
